CAMSYLATE SALT OF (1R,1R,4R)- 4-METHOXY-5"-METHYL-6-[5-(PROP-1-YN-1-YL)PYRIDIN- 3-YL]-3H-DISPIRO[CYCLOHEXANE-1,2-INDEN-12-IMIDAZOLE]-4"-AMINE AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF A[BETA]-RELATED PATHOLOGIES SUCH AS E.G. ALZHEIMERS DISEASE
A process for the preparation of a camsylate salt ((1S)-(+)-10 camphorsulfonic acid) of (1r,1R,4R)- 4-methoxy-5"-methyl-6-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3H-dispiro[cyclohexane-1,2-inden-12-imidazole]-4"-amine is disclosed as well as pharmaceutical compositions containing the salt and therapeutic uses of the salt for treating A²-related pathologies such as Alzheimers Disease, Downs Syndrome, ²-amyloid angiopathy and conditions such as dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinsons Disease, progressive supranuclear palsy or cortical basal degeneration.
